Dr Thomas Parr has been appointed chief scientific officer of Targanta Therapeutics Inc (formerly PhageTech Inc), a private biopharmaceutical firm developing new classes of antibiotics based on its work with phage genomics (bacterial viruses). Parr was formerly with Adaptive Therapeutics, VP R&D at Embiosis Pharmaceuticals and senior director of microbiology with Xenogen Corp. He holds a PhD from the Univ of Calgary….